Finding. Trypanosoma cruzi makes CD8 T cells metabolically sloppy, and an NAD precursor can tidy the mitochondria enough to cut parasite load. Hellriegel, Stempin and colleagues watch parasite-specific CD8 cells in acute infection lean on glycolysis, lose mitochondrial homeostasis, make mitochondrial ROS, and raise CD38. Nicotinamide riboside raises intracellular NAD+ in those cells, improves mitochondrial function, drops mROS, CD38 and apoptosis, and sharpens effector function in the dish and in the mouse. Parasitemia and skeletal-muscle parasites fall. A short NR course is still visible in memory CD8 cells once the infection is chronic.
Why this paper matters
Chagas control is a CD8 job. If the job fails because the T-cell mitochondrion and NAD pool failed first, a vitamin-like precursor is a host-directed experiment worth running, not a parasite-drug substitute. CD38 as the NAD consumer is the mechanistic hint. Muscle burden is the tissue that matters for later cardiomyopathy.
What they actually measured
Infection immunology, NR, NAD+, mitochondrial and death readouts, acute burden, chronic memory. No human arm.
How to read the score
Mid 80s. In vivo control plus a CD8 mitochondrial mechanism. Confidence is high for the mouse.
Caveats
Not a cure. NR can do many things. Check whether the parasite enjoyed the NAD too.
What to do with it
If you model Chagas CD8 cells, add NAD+/CD38/mROS to the panel and an NR arm. If you run chronic cardiomyopathy studies, test a pulse, not lifelong NR, because they already saw a memory echo. Do not give patients NR for Chagas from this brief.